Shanghai Kehua Bio-engineering Co Ltd.
002022
Overview
Corporate Details
- ISIN(s):
- CNE000001KC9
- LEI:
- Country:
- China
- Address:
- N/A
- Website:
- N/A
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
Automate Your Workflow. Get a real-time feed of all Shanghai Kehua Bio-engineering Co Ltd. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Shanghai Kehua Bio-engineering Co Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Shanghai Kehua Bio-engineering Co Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Clinical-stage firm developing precision cancer therapies via synthetic lethality.
United States of America
IDYA
United States of America
IDYA
Develops and commercializes small-molecule medicines for CNS, cardiovascular, and immune disorders.
Switzerland
IDIA
Switzerland
IDIA
Develops & manufactures pharmaceuticals, APIs, and offers CMO services for various diseases.
South Korea
249420
South Korea
249420
Develops pharmaceuticals like antibiotics and anesthetics, expanding into CNS and GI therapies.
South Korea
003120
South Korea
003120
Develops & manufactures drugs, vaccines & supplements for oncology & gastroenterology needs.
South Korea
007570
South Korea
007570
A clinical-stage biopharma developing immuno-oncology agents and bispecific antibodies for cancer.
United States of America
IMAB
United States of America
IMAB
A clinical-stage biopharma pioneering therapies for immune & inflammatory diseases.
United States of America
IMA
United States of America
IMA
Develops a drug delivery platform using ultrasound and nanotech for oncology.
South Korea
456570
South Korea
456570
Develops T-cell redirecting immunotherapies (ACT & TCR Bispecifics) for solid tumor cancers.
United States of America
IMTX
United States of America
IMTX